Orchard Therapeutics ADR Aktie

LONDON and BOSTON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients around the globe, today announced nine presentations from across its late-stage neurometabolic hematopoietic stem cell (HSC) gene therapy portfolio will be featured at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium taking place September 3-6 in Porto, Portugal. » Mehr auf globenewswire.com

A nomination to add MLD to the U.S. Recommended Uniform Screening Panel has been submitted by a multi-disciplinary expert working group » Mehr auf globenewswire.com

Sorrento Therapeutics (OTCMKTS:SRNEQ – Get Free Report) and bluebird bio (NASDAQ:BLUE – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability and institutional ownership. Profitability This table compares Sorrento Therapeutics and bluebird bio’s net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets Sorrento Therapeutics N/A N/A N/A bluebird bio -419.64% -34.32% -14.44% Risk and Volatility Sorrento Therapeutics has a beta of 2.25, suggesting that its share price is 125% more volatile than the S&P 500. Comparatively, bluebird bio has a beta of 0.82, suggesting that its share price is 18% less volatile than the S&P 500. Analyst Ratings This is a breakdown of recent ratings and recommmendations for Sorrento Therapeutics and bluebird bio, as provided by MarketBeat.com. Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sorrento Therapeutics 0 0 0 0 N/A bluebird bio 1 6 4 0 2.27 bluebird bio has a consensus price target of $5.74, indicating a potential upside of 457.71%. Given bluebird bio’s higher possible upside, analysts plainly believe bluebird bio is more favorable than Sorrento Therapeutics. Institutional and Insider Ownership 0.0% of Sorrento Therapeutics shares are held by institutional investors. Comparatively, 87.4% of bluebird bio shares are held by institutional investors. 2.6% of Sorrento Therapeutics shares are held by company insiders. Comparatively, 2.1% of bluebird bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Earnings & Valuation This table compares Sorrento Therapeutics and bluebird bio’s gross revenue, earnings per share and valuation. Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sorrento Therapeutics $62.84 million 0.26 -$572.84 million N/A N/A bluebird bio $21.73 million 5.18 -$266.58 million ($0.74) -1.39 bluebird bio has lower revenue, but higher earnings than Sorrento Therapeutics. Summary Sorrento Therapeutics beats bluebird bio on 6 of the 11 factors compared between the two stocks. About Sorrento Therapeutics (Get Free Report) Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease,and pain. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis pain treatment; and ZTlido, a lidocaine topical system for the treatment of post-herpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California. On February 13, 2023, Sorrento Therapeutics, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas. The plan was later approved as Chapter 11 liquidation on November 30, 2023. About bluebird bio (Get Free Report) bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts. » Mehr auf defenseworld.net